Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Securities and Exchange Commission Subpoena Elan for Brain Virus Reports Linked to Tysabri

By Pharmaceutical Processing | September 30, 2009

WASHINGTON (AP) — U.S. financial regulators are demanding drugmaker Elan Corp. turn over records about a potentially lethal brain disease linked to its drug Tysabri, according to a government filing form. The Irish company said it received a subpoena from the Securities and Exchange Commission for documents connected with its announcement last July of two cases of progressive multifocal leukoencephalopathy, or PML. The company disclosed the subpoena in a regulatory filing Tuesday. The SEC is also seeking information on trial results for the company’s experimental Alzheimer’s drug bapineuzumab, which were released last July. PML is a rare but can cause deadly inflammation in the brain. There have been 13 reported cases of PML since mid-2006. Last week the Food and Drug Administration said the risk of the inflammation appears to increase as patients remain on Tysabri. Tysabri is co-marketed with Cambridge, Mass.-based Biogen Idec Inc. for multiple sclerosis and Crohn’s disease. All the PML cases are linked to its use in multiple sclerosis. The drug was approved in November 2004 and pulled from the market the next year due to PML reports. It was reintroduced in July 2006, and Biogen said it is used by 43,000 patients.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards